Cirrhosis - Pipeline Insight, 2024

This “Cirrhosis- Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cirrhosis Understanding

Cirrhosis: Overview

Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver damage. The scar tissue prevents the liver working properly. Cirrhosis is sometimes called end-stage liver disease because it happens after other stages of damage from conditions that affect the liver, such as hepatitis. There are, however, ways to prevent cirrhosis, because the diseases that most commonly lead to it progress slowly, and measures are available to prevent and treat them. Moreover, most cases of hepatocellular carcinoma (HCC) arise in a cirrhotic liver, so cirrhosis prevention is, in fact, also HCC prevention. Cirrhosis can arise in consequence of an exogenous/toxic, infectious, toxic/allergic, immunopathological/autoimmune, or vascular process or an inborn error of metabolism. The typical findings in cirrhosis include: cutaneous signs of liver disease, a firm liver on palpation, and certain risk constellations such as: metabolic syndrome, heavy alcohol consumption and exposure to hepatotoxic substances. Early symptoms of cirrhosis may include: feeling tired or weak, poor appetite, losing weight without trying, nausea and vomiting and mild pain or discomfort in the upper right side of your abdomen. There's no cure for cirrhosis at the moment. However, there are ways to manage the symptoms and any complications and slow its progression. Treating the problem that led to cirrhosis (for example, using anti-viral medicines to treat hepatitis C) can stop cirrhosis getting worse.

Cirrhosis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cirrhosis pipeline landscape is provided which includes the disease overview and Cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve Cirrhosis.

Cirrhosis Emerging Drugs Chapters

This segment of the Cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cirrhosis Emerging Drugs

GXHPC 1: GWOXI Stem Cell Applied Technology GXHPC1 therapy preparation contains adipose-derived mesenchymal stem cells (AD-MSCs) and was developed for the treatment of liver cirrhosis. The animal studies suggested that treatment of a diseased liver via GXHPC1 transplantation can abrogate liver fibrosis and facilitate recovery of liver function. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of LiverCirrhosis.

LPCN 1148: Lipocine LPCS 1148 is an oral prodrug of bioidentical testosterone being developed for the management of symptoms associated with cirrhosis. Currently, the drug is in Phase II of clinical trial evaluation for the treatment ofcirrhosis.

Belapectin: Galectin Therapeutics Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Currently, the drug is in Phase II/III stage of clinical trial evaluation for the treatment of Cirrhosis.

Cirrhosis: Therapeutic Assessment

This segment of the report provides insights about the different Cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cirrhosis

There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cirrhosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cirrhosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cirrhosis drugs.

Cirrhosis Report Insights

• Cirrhosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cirrhosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cirrhosis drugs?
• How many Cirrhosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cirrhosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cirrhosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cirrhosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GWOXI Stem Cell Applied Technology
• Lipocine
• Galectin Therapeutics
• Pharmicell Co., Ltd.
• BioVie
• Ocera Therapeutics
• Gilead Sciences
• Chia Tai Tianqing Pharmaceutical Group
• Zydus Cadila
• Novartis Pharmaceuticals
• Genfit
• PRISM Pharma Co
• Bristol-Myers Squibb
• COUR Pharmaceutical Development Company, Inc.
• High TideBiopharma
• Gannex Pharma Co., Ltd.

Key Products

• Belapectin
• GXHPC 1
• LPCN 1148
• Cellgram-LC
• BIV-201
• Ornithine phenylacetate
• CILO
• TQA 3526
• Saroglitazar
• LDE225
• Elafibranor
• OP-724
• BMS 986263
• CNP-104
• HTD 1801
• ASC42

This product will be delivered within 1-3 business days.